Page 51 - brain-eBook
P. 51

Team Project Name                                  establish Taiwan's influence in precision health.

            Innovative deep brain stimulation technology and   Key Words
            precision mental illness diagnosis and treatment platform  Precision Psychiatry; Deep Brain Stimulation; Blood-
            Research Project                                   Based Biomarker; Schizophrenia; Bipolar Disorder;
            The diagnosis of mental illness currently relies on   Major Depression
            symptomatic criteria as well as medical history and lacks   Global Cooperation
            objective instrument diagnosis. Also, current psychiatric
            medicine, whether in diagnosis or treatment, is still highly   Our team has established a close academic
            dependent on experience-based rules and lacks precise   collaboration with Professor Matcheri S. Keshavan from
            treatment technology. Therefore, psychiatry urgently   the Department of Psychiatry at Harvard Medical School,
            needs to develop precise diagnoses and new treatment   focusing on exploring brain biomarkers associated with
            technologies. This project proposes the "Innovative   mental illnesses. Additionally, we are privileged to be
            Deep Brain Stimulation Technology and Precise Mental   affiliated with the ENIGMA Consortium, collaborating
            Illness Diagnosis and Treatment Platform." We will   intensively with its scholars who specialize in the study
            develop four innovative brain technologies, including   of schizophrenia, bipolar disorder, and major depressive
            (1) personalized brain lesion localization technology, (2)   disorder. Monthly academic discussions are held with
            novel blood biomarker diagnostic technology, (3) deep   the consortium's expert teams, where we jointly delve
            brain stimulation localization and electric field simulation   into the latest research outcomes and findings. It is
            technology, and (4) a novel brain deep stimulation   noteworthy that the ENIGMA Consortium is globally
            technology (Temporal Interference Brain Stimulation,   recognized as the premier institution in neuroimaging
            TIBS). We will focus on three major mental illnesses,   and genomics research, bringing together research
            including schizophrenia, bipolar disorder, and major   teams from over 26 countries. The consortium's primary
            depression, and use structural and functional MRI and   mission is to harness neuroimaging and genetic data for
            novel blood biomarkers to establish a rapid diagnosis   an in-depth understanding of brain structure, function,
            and identify abnormal brain regions that are related to   and pathologies. Furthermore, in collaboration with
            cognitive function decline and core psychiatric symptoms   Professor Niels Kuster's team at the Eidgenössische
            qualitatively and quantitatively. Through the localization   Technische Hochschule Zürich (ETH Zürich), we are
            of abnormal brain regions, we will use electric field   developing cutting-edge Temporal Interference Brain
            simulation technology to optimize the parameters of   Stimulation (TIBS) with the aspiration of constructing
            TIBS for human safety validation and conduct clinical   comprehensive therapeutic devices. These devices
            trials to treat the three major mental illnesses. We   undergo clinical trials and human safety evaluations
            expect to establish a precision psychiatry platform for   for mental disorders. We anticipate collaborating with
            the diagnosis and treatment of mental illnesses such as   Professor Yang C. Fann from the National Institutes
            schizophrenia, bipolar disorder, and major depression   of Health in the United States to integrate a federated
            and to optimize treatment parameters and methods for   learning framework into our artificial intelligence model,
            deep brain stimulation technology for treating these   aiming to enhance its precision and stability.
            diseases through human safety validation and clinical   Project Web Page
            trials. Ultimately, we will complete patent applications
            in Taiwan and internationally, submit applications for
            medical device approval, collaborate with the IT industry
            for product commercialization, and work with clinical
            institutions in Taiwan and internationally. This project
            will stimulate the development of the neurotechnology
            industry, improve the well-being of the people, and
 50                                                                                                          51
   46   47   48   49   50   51   52   53   54   55   56